Specific aims: The first part of this application aims at understanding the biological significance of the NK system as a mechanism to maintain homeostasis in the hematopoietic system and to avoid extra medullary hematopoiesis. Given the ability of NK cells to inhibit normal progenitor cells in the bone marrow, possible consequences of an over-activated NK system may be dysfunction of the bone marrow, and example of this in man and mouse experimental systems will be analyzed. A better understanding of the ability of NK cells to inhibit growth and metastatic spread of tumor cells is the aim of part 2 in this application. The possibility that quantitative variations of MHC-1 expression affects tumorogenicity and metastatic spread of tumor cells will be investigated. With increased knowledge about how lymphokines affect tumor sensitivity and how NK cells can be used in adoptive transfer models, the study aim at helping to improve immunotherapy protocols. Methodology: Chronic suppression of NK activity by in vivo administration of NK - specific antibodies, or activation of NK cells by acute virus infection, will be performed in mouse experimental system. The consequences of these treatments on the frequency of pluripotent, myeloid and erythroid progenitor cells will be analyzed by in vivo spleen colony assays or in vitro agar assays. Aplastic anemia and leukopenia in man will be analyzed as possible examples of conditions where the immune system, including NK cells may play a role. Factors produced by lymphocytes of these patients will be characterized purified and cloned. The consequences on tumor NK sensitivity, tumorogenicity and metastatic spread of modulation of MHC-1 expression by interferons or in vivo passage of tumor cells will be analyzed. The proteins and genes responsible for confering NK protection to tumor cells as a consequence of IFN-gamma treatment will be investigated by 2-D gels and by cDNA subtraction methods. Long-term objectives: A deeper understanding of the biological significance of the NK system as a regulator of hematopoiesis and as a tumor surveillance mechanism will make it possible to in a controlled manner up- or down-regulate host NK activity. This may have positive consequences in the therapy of patients suffering from malignant tumors or from dysfunction of the bone marrow caused by the immune system.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA044882-03
Application #
3187724
Study Section
Immunobiology Study Section (IMB)
Project Start
1987-06-01
Project End
1990-05-31
Budget Start
1989-06-01
Budget End
1990-05-31
Support Year
3
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Karolinska Institute
Department
Type
DUNS #
350582235
City
Stockholm
State
Country
Sweden
Zip Code
171 77
Ferm, M; Gronberg, A; Tally, M (1996) IFN-gamma treatment increases insulin binding and MHC class I expression in erythroleukemia cells. Immunol Invest 25:37-47
Algarra, I; Silva, S; Ljunggren, H G (1993) MHC class I expression on prelymphomatous and lymphomatous B-cells is not inhibited by an E mu-myc transgene. Eur J Cancer 29A:238-41
Carbone, E; Stuber, G; Andree, S et al. (1993) Reduced expression of major histocompatibility complex class I free heavy chains and enhanced sensitivity to natural killer cells after incubation of human lymphoid lines with beta 2-microglobulin. Eur J Immunol 23:1752-6
Gigliotti, D; Nihlmark, E L; Wigzell, H et al. (1992) Murine thymocytes with ability to inhibit Il-2 production: I. Genetic differences between mouse strains and characterization of the model system. APMIS 100:71-80
Glas, R; Sturmhofel, K; Hammerling, G J et al. (1992) Restoration of a tumorigenic phenotype by beta 2-microglobulin transfection to EL-4 mutant cells. J Exp Med 175:843-6
Ferm, M T; Gronberg, A (1991) Human MHC class I antigens are associated with a 90-kDa cell surface protein. Scand J Immunol 34:221-7
Hoglund, P; Glas, R; Ohlen, C et al. (1991) Alteration of the natural killer repertoire in H-2 transgenic mice: specificity of rapid lymphoma cell clearance determined by the H-2 phenotype of the target. J Exp Med 174:327-34
Gigliotti, D; Ferm, M; Wigzell, H et al. (1991) A monoclonal IgM antibody to a methylcholanthrene-induced tumor. 2. A biologically relevant glycoprotein antigen with a molecular weight of 40-43 kilodaltons. Tumour Biol 12:217-24
Bernell, P; Pisa, P; Hast, R et al. (1991) Increase of serum interleukin-2 and regression of myeloma after rhGM-CSF treatment of drug induced bone marrow aplasia. Hematol Oncol 9:129-35
Naganuma, H; Kiessling, R; Patarroyo, M et al. (1991) Increased susceptibility of IFN-gamma-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: participation of ICAM-1 induction on target cells. Int J Cancer 47:527-32

Showing the most recent 10 out of 33 publications